Senator Bernie Sanders has blasted Novo Nordisk’s CEO Lars Fruergaard Jørgensen over the high cost of Ozempic and Wegovy in the US in a 24 September Senate hearing, with Jørgensen stating that the firm was open to potential talks with pharmacy benefit managers after Sanders suggested that generic rivals could step in at a much lower price.
Sanders Mulls Generic Possibilities As He Blasts Novo Over High Ozempic And Wegovy Prices
Suggests Generics Could Sell For $100 A Month; Novo CEO Open To Potential Talks With PBMs
In a closely anticipated US Senate Committee hearing, Novo’s CEO was grilled by US senator Bernie Sanders and others on the high price of Ozempic and Wegovy in the country.
